QualityStocks'  Instablog

Although great strides have been made in the prevention and treatment of cervical cancer, there are still over 12,000 newly diagnosed cases in the U.S. every year. In addition, approximately ½ million patients every year are diagnosed with high grade cervical intraepithelial neoplasia (CIN 2/3), the predecessor condition to cervical cancer. Cervical cancer is associated with Human Papilloma Virus, a very common virus that can affect the cells of the cervix. About 57% of cervical cancer is the result of infection by Human Papilloma Virus strain 16 (HPV-16). In 2009, the CDC reported that about 45% of women aged 20 to 24 had HPV. HPV causes a number of other types of cancer as well. In developing countries around the world, the situation is even worse. In India, for example, over 72,000 women died of cervical cancer in 2008.

Advaxis is a biotechnology company developing therapeutic immunotherapies targeting HPV-associated diseases: cervical intraepithelial neoplasia (CIN 2/3), recurrent or refractory cervical cancer, as well as head and neck cancer. They have also developed immunotherapies for prostate cancer and HER2 expressing cancers (such as breast, gastric, bladder, brain, pancreatic, ovarian cancer, and canine osteosarcoma).

Advaxis immunotherapies are based on a unique platform technology that uses live, attenuated bacteria, bio-engineered to secrete an antigen/adjuvant fusion protein that redirects the powerful immune response all human beings have to the cancer itself. The company currently has more than fifteen constructs in various stages of development, either developed directly by Advaxis or through strategic collaborations with recognized centers of excellence, such as the National Cancer Institute, Cancer Research - UK, the Wistar Institute, and the University of Pennsylvania, among others. ADXS-HPV, the company's first construct, is being evaluated in 4 Phase 2 clinical trials for HPV associated diseases (CIN 2/3, cervical cancer, and head and neck cancer).

For additional information, visit Advaxis.com

Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net